Complement inhibitor therapy should be available to patients with paroxysmal nocturnal hemoglobinuria throughout the world

International Journal of Hematology · Published 2026-08-04 · DOI 10.1007/s12185-026-04261-8

Authors (1)

Lucio Luzzatto

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Luzzatto, L. (2026). Complement inhibitor therapy should be available to patients with paroxysmal nocturnal hemoglobinuria throughout the world. International Journal of Hematology. https://doi.org/10.1007/s12185-026-04261-8

Related articles

• Recent advances in the pathophysiology and treatment of GVHD · International Journal of Hematology · 2026 · Same journal
• Immunological links between aplastic anemia and paroxysmal nocturnal hemoglobinuria · International Journal of Hematology · 2026 · Same journal
• Current status and challenges of TCR-T cell therapy for AML/MDS · International Journal of Hematology · 2026 · Same journal
• T-cell fitness, metabolic tumor volume, and serum LDH levels are associated with response to axicabtagene ciloleucel · International Journal of Hematology · 2026 · Same journal
• NPM1-rearranged AML: clinical features, molecular pathogenesis, and therapeutic perspectives · International Journal of Hematology · 2026 · Same journal
• Postmarketing surveillance study of asciminib in patients with resistant/intolerant chronic myeloid leukemia in Japan · International Journal of Hematology · 2026 · Same journal
• Genomic insights transform diagnosis, prognosis, and therapy in BCR::ABL1-negative myeloproliferative neoplasms · International Journal of Hematology · 2026 · Same journal
• Defibrotide for late-onset sinusoidal obstruction syndrome following umbilical cord blood transplantation: a single-center retrospective study · International Journal of Hematology · 2026 · Same journal
• Zanubrutinib for MYD88-negative Waldenström’s macroglobulinemia with massive splenomegaly · International Journal of Hematology · 2026 · Same journal
• Darbepoetin alfa for the treatment of anemia in myelodysplastic syndromes: a post-marketing surveillance study in Japan · International Journal of Hematology · 2026 · Same journal